KCTBASE

Cancer immunotherapy using tumor antigen-reactive T cells.

Choi, Beom K; Kim, Seon-Hee; Kim, Young H; Kwon, Byoung S

Immunotherapy
2018Mar ; 10 ( 3 ) :235-245.

PMID : 29370726

저자 상세정보

Choi, Beom K -
Kim, Seon-Hee -
Kim, Young H -
Kwon, Byoung S -

ABSTRACT

Studies over the last 30 years have shown the promise of cancer immunotherapy using T cells. In particular, since the report by Rosenberg and colleagues in 2002 that adoptive T-cell therapy (ACT) under lymphopenic conditions substantially increased response rates in melanoma patients, ACT has become a promising immunotherapeutic route to cancer treatment. Here we provide a brief history of ACT and review the characteristics of T-cell therapeutics that are specific to this approach. Since every T-cell treatment has its own unique properties in terms of number and type of target antigens, and number of epitopes and type of T cells, we review the main strategies for designing ACT: how Ag specificity is determined, how is it standardized and the need for lymphodepletion to induce epitope spreading. We also briefly consider the next generation of ACT.

keyword

adoptive cell therapy; lymphodepletion; standardization

링크

PubMed

주제코드

주제명(Target field)

연구대상(Population)

연구참여(Sample size)

대상성별(Gender)

질병특성(Condition Category)

연구환경(Setting)

연구설계(Study Design)

연구기간(Period)

중재방법(Intervention Type)

중재명칭(Intervention Name)

키워드(Keyword)

유효성결과(Recomendation)

This article reviewed the main strategies for designing ACT: how Ag specificity is determined, how is it standardized and the need for lymphodepletion to induce epitope spreading. We also briefly consider the next generation of ACT.

연구비지원(Fund Source)

근거수준평가(Evidence Hierarchy)

출판년도(Year)

참여저자수(Authors)

대표저자

DOI

10.2217/imt-2017-0130.

KCD코드

ICD 03

건강보험코드